Novartis Ag (NVS) Long-Term Debt Issuances (2017 - 2025)
Novartis Ag's (NVS) quarterly Long-Term Debt Issuances came in at $135.0 million in Q3 2025, down 94.54% quarter-over-quarter from $2.5 billion in Q4 2024.
Novartis Ag (NVS) Long-Term Debt Issuances (2017 - 2025) Analysis & Trends
Novartis Ag has disclosed Long-Term Debt Issuances across 4 years of filings, most recently posting $135.0 million for Q3 2025.
- Long-Term Debt Issuances for Q3 2025 came in at $135.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $5.2 billion (changed N/A YoY), and the FY2025 annual result was $6.1 billion, down 0.73% from the prior year.
- Long-Term Debt Issuances came in at $135.0 million for Q3 2025 at Novartis Ag, down from $2.5 billion in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $2.5 billion in Q2 2024 to a low of $135.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 135.00 Mn |
| Sep 30, 2025 | 135.00 Mn |
| Dec 31, 2024 | 2.47 Bn |
| Dec 31, 2024 | 2.47 Bn |
| Jun 30, 2024 | 2.47 Bn |
| Jun 30, 2024 | 2.47 Bn |
| Jun 30, 2018 | 91.00 Mn |
| Jun 30, 2018 | 91.00 Mn |
| Jun 30, 2017 | 2.00 Mn |
| Jun 30, 2017 | 2.00 Mn |